t
| Date | 19 Jan 2023 |
| Time | 07:00:03 |
| Category | Miscellaneous |
| ID | 1761N |
Celadon Pharmaceuticals Plc
Change of Website Address
London, 19 January 2023 - Celadon Pharmaceuticals Plc (AIM: CEL), announces that its website address has changed to www.celadonpharma.com with immediate effect. The information required pursuant to AIM Rule 26 can be found at this address.
Enquiries:
|
Celadon Pharmaceuticals Plc |
|
|
James Short Arthur Wakeley |
Via Powerscourt |
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Bobbie Hilliam / Andrew Potts / Patrick Dolaghan |
+44 (0)20 7523 8000 |
|
|
|
|
Powerscourt Group |
|
|
Sarah MacLeod / Nick Johnson / Sam Austrums / Ibrahim Khalil |
+44 (0)20 7250 1446
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility comprises a laboratory designed to meet GMP standards, and capacity for a large indoor hydroponic growing facility that has received a Home Office Licence to legally grow high-THC medicinal cannabis for the purpose of producing test batches of cannabis oil to support its application to the MHRA. The Company's subsidiary, LVL, owns a MHRA conditionally-approved cannabis trial using cannabis based medicinal products to treat chronic pain in the UK.
For further information please visit our website www.celadonpharma.com.